Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hospital Corporation of China Limited 弘和仁愛醫療集團有限公司 (Incorporated in the Cayman Islands with limited liability)

(Stock code: 3869)

ANNOUNCEMENT OF (1) CHANGE IN DIRECTORS AND (2) CHANGE IN MEMBERS OF AUDIT COMMITTEE AND REMUNERATION COMMITTEE

RESIGNATION OF NON-EXECUTIVE DIRECTOR AND MEMBER OF AUDIT COMMITTEE AND REMUNERATION COMMITTEE

The board (the "**Board**") of directors (the "**Directors**", and each, a "**Director**") of Hospital Corporation of China Limited (the "**Company**") hereby announces that Mr. Lin Sheng ("**Mr. Lin**") has tendered his resignation as a non-executive Director of the Company, a member of the audit committee of the Company (the "**Audit Committee**") and a member of the remuneration committee of the Company (the "**Remuneration Committee**") with effect from March 12, 2019 due to his other work commitment.

Mr. Lin has confirmed that he has no disagreement with the Board and there is no matter in relation to his resignation that needs to be brought to the attention of the shareholders of the Company.

APPOINTMENTOFEXECUTIVEDIRECTOR,**NON-EXECUTIVEDIRECTORANDMEMBERSOFAUDITCOMMITTEEANDREMUNERATIONCOMMITEE**

The Board further announces that with effect from March 12, 2019, (i) Mr. SHAN Guoxin ("**Mr. Shan**") has been appointed as an executive Director of the Company and (ii) Mr. WEI Kai ("**Mr. Wei**") has been appointed as a non-executive Director of the Company.

The Board has appointed Mr. Shan as a member of the Remuneration Committee and Mr. Wei as a member of the Audit Committee, with effect from March 12, 2019.

Set out below are the biographies of Mr. Shan and Mr. Wei and other information to be disclosed pursuant to rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules"):

Mr. SHAN Guoxin

The biographical details of Mr. Shan are set out as follows.

Mr. Shan, aged 57, has over 30 years of experience in the management of hospitals and healthcare groups, investment in hospitals and hospital operations. Prior to joining the Group, he was the deputy director of medical education department at Zhujiang Hospital, an affiliate hospital of First Military Medical University (currently known as Southern Medical University) (第一軍醫大學(現南方醫科大學) 附屬珠江醫院). Since 2005, Mr. Shan served as the assistant to hospital administrator, vice hospital administrator, executive hospital administrator and hospital administrator of Guangdong 999 Neurology Hospital (廣東三九腦科醫院), a Class IIIA specialty hospital. From November 2012 to November 2016, he also served as the Chief Operating Officer and vice general manager of China Resources Healthcare Group (華潤醫療集團), and in the meantime as the hospital administrator of Xuzhou Mining Hospital (徐州市礦山醫院), a Class IIA general hospital under China Resources Healthcare Group.

Mr. Shan graduated from the First Military Medical University (Guangzhou) (第一軍 醫大學(廣州)) in August 1984 with major in military clinical medicine. He completed his postgraduate program at First Military Medical University in August 1995 and has attended various educational programs, including hospital management program at Second Military Medical University (第二軍醫大學), EMBA program at South China University of Technology (華南理工大學), public relations courses (through correspondence) at Language and Logic University of China (中國語言與邏輯函授大 學), and economic management courses (through correspondence) at Central Party School of the Communist Party of China (中共中央黨校). Mr. Shan became a vice professor at First Military Medical University in October 1995 and had served as the chairman of Guangdong Community Health Association (廣東社區衛生學會). Mr. Shan has entered into a service contract with the Company regarding his appointment as the executive Director of the Company. Mr. Shan will hold office only until the first general meeting of the Company after his appointment and shall then be eligible for re-election at that general meeting, and thereafter subject to retirement by rotation at least once every three years at each annual general meeting, in accordance with the memorandum and articles of association of the Company. Mr. Shan will not receive any directors' fees from the Company, but is entitled to an annual salary and bonus of RMB4,500,000 as the Chief Executive Officer of the Company (as stated in the announcement of the Company dated June 5, 2018).

Mr. WEI Kai

Mr. Wei Kai (魏凱), aged 42, is currently an executive director of the innovative consumption and service investment division of Legend Holdings Corporation ("Legend Holdings"). He joined Legend Holdings in February 2008, and has been mainly responsible for strategic investment in innovation consumption and medical services sectors, as well as post—investment management of investment targets in the related fields. Prior to joining Legend Holdings, Mr. Wei worked in the department of strategy and investment management within China International Television Corporation, and his responsibilities were subsidiary management and strategic investments in media-related fields.

Mr. Wei obtained his master's degree in business administration from Tsinghua University (清華大學) in 2004 and his bachelor's degree in thermal engineering from Jilin University (吉林大學) (formerly known as Jilin University of Technology (吉林工業大學) in 1998.

Mr. Wei has entered into a service contract with the Company regarding his appointment as the non-executive Director of the Company. Mr. Wei will hold office only until the first general meeting of the Company after his appointment and shall then be eligible for re-election at that general meeting, and thereafter subject to retirement by rotation at least once every three years at each annual general meeting, in accordance with the memorandum and articles of association of the Company. Mr. Wei will not receive any director's fee from the Company. As at the date of this announcement, Mr. Shan and Mr. Wei (i) do not have any interest in or are not deemed to be interested in any shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) do not hold any other positions in the Company or other members of the Group; and (iii) do not have any relationship with any Directors, other senior management, or controlling or substantial shareholders (as respectively defined in the Listing Rules) of the Company.

Save as disclosed above, there is no further information relating to the appointments of Mr. Shan and Mr. Wei that needs to be disclosed pursuant to any of the requirements under Rule 13.51(2) of the Listing Rules.

The Board would like to express its warmest welcome to Mr. Shan and Mr. Wei on their appointments.

By order of the Board Hospital Corporation of China Limited Zhao John Huan Chairman

Beijing, China, March 12, 2019

As at the date of this announcement, the directors of the Company are Mr. SHAN Guoxin and Mr. LU Wenzuo being the executive directors; Mr. ZHAO John Huan, Ms. LIU Lu, Ms. WANG Nan and Mr. WEI Kai being the non-executive directors; Ms. CHEN Xiaohong, Mr. SHI Luwen and Mr. ZHOU Xiangliang being the independent non-executive directors.